Bayer has decided to discontinue a phase 3 trial of its oral Factor XIa inhibitor asundexian in patients with atrial fibrillation ... Factor Xa inhibitor Eliquis (apixaban) in AF patients at ...

The Global Coagulation Monitoring Products Market is expected to reach at a CAGR of 5.6% during the forecast period 2025-2033. The Coagulation Monitoring Products Market is growing due to rising ...

Two Phase III trials found that apixaban was more effective for stroke prevention than either aspirin or warfarin in patients with atrial fibrillation (AF), with a similar (versus aspirin ...

Atrial fibrillation (AF) is the most common cardiac ... Novel anticoagulants include dabigatran, rivaroxaban and apixaban. Based on the RE-LY study, a 150-mg dose of dabigatran as compared with ...

Any thoughts on milk thistle supplements in fatty liver disease that was diagnosed by an ultrasound due to elevated AST and ...

In December, the U.S. Food and Drug Administration (FDA) approved a new treatment for people with insomnia, Dayvigo (lemborexant). The drug will be available in 5 or 10 milligram (mg) doses ...

The drug was given accelerated approval in the US in 2022, which was upgraded to full approval a year ago, and was also cleared in Europe last November. AbbVie has pointed to a very strong launch ...

set by the Food and Drug Administration (FDA). How we evaluate vitamins, minerals, and supplements Our Medical Standards and Insights team has carefully researched and vetted over 11,000 products ...